Information about Etravirine
Etravirine is a nonnucleoside reverse transcriptase inhibitor used in combination with other agents in the therapy of human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS).
Liver safety of Etravirine
Mechanism of action of Etravirine
Etravirine (e" tra vir' een) is a “second generation” nonnucleoside reverse transcriptase inhibitor that acts by noncompetitive binding to the HIV reverse transcriptase and indirectly inactivating its catalytic site. Etravirine is similar to nevirapine and efavirenz in its mechanism of action, but shares minimal structural features. Etravirine has a higher barrier to development of resistance than nevirapine and efavirenz, at least in vitro.
FDA approval information for Etravirine
Etravirine was approved for use in the United States in 2007, and current indications are as therapy of HIV infection in combination with other agents in antiretroviral treatment-experienced adult patients.
Dosage and administration for Etravirine
Etravirine is available in tablets of 25, 100 and 200 mg under the brand name Intelence. The recommended dosage in adults is 200 mg orally twice daily.
Side effects of Etravirine
Common side effects include fatigue, dizziness, headache and skin rashes. Less common but potentially serious side effects include peripheral neuropathy, lipodystrophy, immune reconstitution syndrome, and hypersensitivity reactions including erythema multiforme, Stevens Johnson syndrome and toxic epidermal necrolysis.
Drugs for HIV Infection, in the Subclass Antiretroviral Agents
- Nonnucleoside Reverse Transcriptase Inhibitors (HIV)
- Nucleoside Analogues (HIV)
- Protease Inhibitors (HIV)
HCV NS5A Inhibitors
HCV NS5B (Polymerase) Inhibitors
- Asunaprevir, Boceprevir, Glecaprevir, Grazoprevir, Paritaprevir, Simeprevir, Telaprevir, Voxilaprevir
Drugs for Herpes Virus Infections (HSV, CMV, others)
Drugs for Influenza